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Abstract 
We report on the synthesis, characterization, stability and pharmacokinetics of novel iron based 
contrast agents for magnetic resonance imaging (MRI). Statistical copolymers combining 
multiple phosphonic acid groups and poly(ethylene glycol) (PEG) were synthesized and used as 
coating agents for 10 nm iron oxide nanocrystals. In vitro, protein corona and stability assays 
show that phosphonic acid PEG copolymers outperform all other coating types examined, 
including low molecular weight anionic ligands and polymers. In vivo, the particle 
pharmacokinetics is investigated by monitoring the MRI signal intensity from mouse liver, spleen 
and arteries as a function of the time, between one minute and seven days after injection. Iron 
oxide particles coated with multi-phosphonic acid PEG polymers are shown to have a blood 
circulation lifetime of 250 minutes, i.e. 10 to 50 times greater than that of recently published 
PEGylated probes and benchmarks. The clearance from the liver takes in average 2 to 3 days 
and is independent of the core size, coating and particle stability. By comparing identical core 
particles with different coatings, we are able to determine the optimum conditions for stealth 
MRI probes. 
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1 – Introduction 
Magnetic Resonance Imaging (MRI) is one of the most widespread non-invasive imaging 
techniques in clinical practice and research. Current MRI methods are based on the intrinsic 
contrast of soft tissues and vessels, and provide important information on a broad range of 
pathologies. Novel imaging techniques have emerged over the last decade, in particular 
techniques based on the use of contrast agents.1-3 Most studied MRI contrast agents are 
gadolinium chelates and magnetic particles. Made from iron oxide, magnetic particles provide 
several advantages among which a substantial biodegradability over time and an absence of 
cytotoxicity. In addition, depending on their size the particles can be used as positive or 
negative contrast agents, leading to an enhancement of longitudinal and transverse proton 
relaxation rates.4-6 
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For applications, the pharmacokinetic profile of the MRI probes has to be known. Absorption, in 
vivo biodistribution, metabolic transformation and elimination from the tissues and organs are 
the primary mechanisms involved in pharmacokinetics. In the blood pool, nanoparticles 
administered intravenously are recognized from plasma proteins, which adsorb at the particle 
surface spontaneously.7-12 The protein binding process, known as the protein corona formation 
prevents the particles to interact specifically with potential targets. Simultaneously, protein 
adsorption activates the particle uptake by the mononuclear phagocytic system through the 
circulating macrophages and monocytes. The two-step opsonization mechanism described here 
is responsible for the particle elimination from the blood stream and for their accumulation in 
unrelated organs, typically the liver and the spleen.13 As a result, commercial contrast agents 
using iron oxide cores (e.g. Endorem® from Guerbet, Resovist® and Cliavist® from Bayer) 
were first designed for imaging hepatic lesions and tumors.1 Ever since, iron oxide particles 
have been surveyed in the context of other clinical applications, including heart transplantation, 
brain lesions imaging and tumor targeting.2,6,14-16 
To prevent opsonization, studies have shown that neutral hydrosoluble polymers such as 
poly(ethylene glycol) (PEG) or polysaccharides are efficient.13,17-20 Tethered at the chain 
extremity or from several monomeric units, the polymers in aqueous environment form a 
swollen brush that acts as a protective layer against protein adsorption and particle aggregation. 
In this context, efforts were mainly directed towards the molecular weight effect on the in vitro 
stability and in vivo stealthiness.15,21-27 From in vivo pharmacokinetics studies, Leal et al. have 
found an optimum PEG value of 3 kDa,25 whereas particle accumulation in tumor was found to 
be efficient with 10 kDa polymers.15 Recently, Ruiz et al. reported a doubling of the residence 
time in blood for PEG conjugated iron oxide particles, and a reduction in the liver and spleen 
uptake.21,22 In some of the previous studies, the PEGylated contrast agents tested were 
prepared from 10 nm particles; however it was found that during synthesis or functionalization 
the particles aggregated and formed large clusters containing tens to hundreds of 
particles.15,21,22,26,28 For aggregates, additional parameters such as size and morphology were 
found to affect the MRI contrast properties and the biodistribution in vivo. These properties were 
also different from those of single nanoparticles. 
Another crucial issue in particle functionalization is the nature and strength of the link between 
the coat and the inorganic surface. A wide variety of techniques based on covalent or non-
covalent binding are now achievable, including ligand adsorption, layer-by-layer deposition or 
surface-initiated polymerization.29 Non-covalent strategies based on the assembly of separately 
synthesized components are known to exhibit enhanced yields in terms of quantity of particles 
produced.30 Novel macromolecular architectures obtained by radical polymerization were also 
considered.31 Na et al. designed multi-dentate catechol and PEG derivatized oligomers that 
provide colloidal stability over a broad range of pH and electrolyte concentrations.32 Single or 
multiple phosphonic acid based polymers were also synthesized.31,33-35 Phosphonate groups are 
known to have a higher affinity towards metallic atoms or metal oxides compared to sulfonates 
and carboxylates, and are hence able to build stronger links with surfaces. Sandiford et al. 
exploited PEG polymer conjugates containing a terminal bis-phosphonic acid group for binding 
to magnetic nanoparticles.34 
We have recently shown that multi-phosphonic acid PEG-copolymers with up to 4 anchoring 
groups per chain conferred considerable stabilization to 10 nm iron oxide cores. The coated 
particles were found to be stable for months in extreme salt and pH conditions, as well as in cell 
culture media. In a previous work, multi-phosphonic acid PEG coated particles were tested 
against fibroblast and macrophage cultures and exhibited exceptional low cellular uptake.12 
Here, these newly coated particles are assessed in vivo using a live mouse model. MRI is 
particularly suited for this study as it provides spatial and temporal resolved images with high 
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contrast. The present survey reveals that the phosphonic acid PEG copolymers with multiple 
anchoring groups are able to prolong the particle lifetime in the blood up to 3 hours, i.e. 50 times 
greater than that of anionic particles or Cliavist® benchmark, and 10 times greater than that of 
recently published PEGylated probes.21-23 A qualitative model taking into account the uptake 
and clearance is proposed and is found to be appropriate for all contrast agents studied. By 
comparing identical core particles with different coating, we are able to determine the optimum 
conditions for stealth MRI probes.  
 
 
2 - Materials & Methods 
2.1 - Iron oxide nanoparticles and Coating 
2.1.1 - Iron oxide nanoparticles 
Iron oxide nanoparticles were synthesized by alkaline co-precipitation of iron(II) and iron(III) 
salts.36,37 The salts were dissolved in a hydrochloric solution and co-precipitated by a 
concentrated base (ammonia, NH3). The particles were then concentrated magnetically and the 
supernatant was removed. The concentrated phase was washed with water using magnetic 
sedimentation followed again by supernatant removal. Nitric acid (HNO3) was then added to the 
particles down to pH 1.5. Addition of a large excess of ferric nitrate at water boiling temperature 
led to the oxidation of magnetite into stable maghemite nanocrystals. The nanoparticles were 
sorted according to their size by successive phase separation steps.38 At pH 1.5, the particles 
are positively charged and have nitrate counterions adsorbed on their surfaces. The resulting 
interparticle interactions are repulsive and impart an excellent stability to the dispersion.37,39 
Here, two γ-Fe2O3 nanoparticles batches (diameter 6.8 nm and 13.2 nm) were synthesized (Figs. 
1a-d). The magnetic and geometric size distributions were obtained from vibrating sample 
magnetometry (VSM) and from transmission electron microscopy (TEM), respectively. Table I 
provides a list of the diameters and dispersities (ratio between standard deviation and average 
diameter) obtained from these two techniques.  
 
	   6.8	  nm	  γ-­Fe2O3	  
nanoparticle	  
13.2	  nm	  γ-­Fe2O3	  
nanoparticle	  
diameter	  VSM	  (nm)	   6.7	   10.7	  
dispersity	  VSM	   0.21	   0.33	  
diameter	  TEM	  (nm)	   6.8	   13.2	  
dispersity	  TEM	   0.18	   0.23	  
molecular	  weight	  𝑀𝑀!
!"#$	  (Da)	   1.3×106	   12×106	  
hydrodynamic	  diameter	  𝐷𝐷!	  
(nm)	  
14	   27	  
 
Table I: Characteristics of the iron oxide particles used in this work. The bare particle size and size 
dispersity were determined by vibrating sample magnetometry (VSM) and by transmission electron 
microscopy (TEM). The weight-averaged molecular weight 𝑀𝑀!!"#$ was obtained from static light 
scattering.40 𝐷𝐷! is the bare particle hydrodynamic diameter in water. 
 
 
The nanoparticle magnetization was also measured using VSM and its value was found slightly 
lower than that of bulk maghemite41,42 (2.9×105 A m-1 instead of 3.9×105 A m-1). The particle 
crystallinity was studied by electron microdiffraction scattering. Five diffraction rings 
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characteristic of the maghemite structure were observed (S1-S4). In the dispersed state, light 
scattering techniques allowed the measurements of the weight-averaged molecular weight and 
of the hydrodynamic diameter for the particles.40 Throughout the paper, the concentrations are 
expressed in terms of the iron molar concentration, noted [Fe]. For instance, the [Fe] = 5 mM 
dispersion used for the intravenous injection corresponds then to a weight concentration of 400 
µg mL-1. Assuming a blood pool of 1 mL for wild-type BALB/c mice (age 8 weeks), the 
concentration of circulating particles is estimated at 40 µg mL-1. The contrast agent used as a 
benchmark, Cliavist® was commercialized by the company Bayer (Germany). According to 
supplier specifications, the Cliavist® dispersion has an iron concentration of 500 mM and 
contains 4 nm magnetic core particles aggregated into 55 to 65 nm clusters.1 The 1400 Da 
carboxydextran molecules used in the formulation serve both as a linker for the maghemite 
nanocrystals, the polymer role being indeed to prevent the dispersion sedimentation.  
 
 
Figure 1: a, b) Transmission electron microscopy (TEM) of the 6.8 and 13.2 nm iron oxide nanoparticles. 
The bars are 20 nm and 50 nm respectively. c, d) Particle size distribution determined by TEM. e) Table 
showing the chemical formula, charge and molecular weight of the organic coatings used in this study. 
For the phosphonic acid PEG copolymer, only the PEG molecular weight is indicated.  
 
 
2.1.2 – Coating 
In this section, we describe the macromolecules and protocols used to coat the iron oxide 
particles (Fig. 1e). Poly(ethylene glycol methacrylate-co-dimethyl(methacryoyloxy) methyl 
phosphonic acid), abbreviated in this work phosphonic acid PEG copolymer was synthesized by 
Specific Polymers®, France (http://www.specificpolymers.fr/). The synthesis was carried out by 
free radical polymerization of PEG-methacrylate (PEGMA, SP-43-3-002, CAS: 26915-72-0) and 
dimethyl(methacryoyloxy)methyl phosphonate (MAPC1, SP-41-003, CAS: 86242-61-7) 
monomers. Synthesis details can be found in previous reports.12,43 The phosphonic acid PEG 
copolymers were characterized from 1H NMR and 31P NMR using a Bruker Avance 300 
spectrometer operating at 300 MHz. For the copolymers, a molar-mass dispersity of 1.8 was 
obtained by size exclusion chromatography on PolyPore column using THF as eluent and 
polystyrene standards. From the molar equivalent of acid groups obtained from NMR and 
molecular weight determination, the number of phosphonic acids and PEG segments was 
estimated. This number was found to be 3.1 ± 0.2 and 3.7 ± 0.2 for copolymers with PEG2K and 
PEG5K, respectively (Table II). Here and below, the error bars are defined as the standard 
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deviations (SD). These determinations confirm the existence of multiple functional groups on the 
same polymer backbone.  
 
polymer	  name	  
acid	  group	  
meq/g	  
functional	  group	  
per	  chain	  
PEG	  
density	  
6.8	  nm	  
PEG	  
density	  
13.2	  nm	  
copolymer	  	  
with	  PEG	  2000	  Da	  
0.873	   3.1	  ±	  0.2	   1.9	   1.1	  
copolymer	  	  
with	  PEG	  5000	  Da	  
0.349	   7.4±	  0.4	   2.0	   1.1	  
 
Table II: Structural parameters of the PEG copolymers used in this work. The first column denotes the 
molar equivalent of acid groups per gram (𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚  𝑒𝑒𝑒𝑒  𝑔𝑔!!) of polymer as determined by 1H NMR. The 
numbers of the functional groups are determined from the molecular weight and from the molar 
equivalent of acid groups.12 The error bars are here defined as the standard deviations (SD). 
 
For the coating, we used a protocol derived in 2008.44,45 Dispersions of oppositely charged iron 
oxides and phosphonic acid PEG copolymers at the same concentration (𝑐𝑐 = 0.1 wt. %) and 
same 𝑝𝑝𝑝𝑝 (𝑝𝑝𝑝𝑝  2) were mixed at increasing volume ratios 𝑋𝑋 between 10-3 and 103. The 𝑝𝑝𝑝𝑝 of the 
mixed solution was then raised to 8 by ammonium hydroxide addition, leading to well-dispersed 
coated particles. The mixed polymer/particle dispersion stability diagram was investigated by 
dynamic light scattering (Fig. S5). By plotting the hydrodynamic diameter against the mixing 
ratio 𝑋𝑋, a transition between individual coated particles and micron-sized aggregates occurs at 
the critical value, 𝑋𝑋!. The existence of a critical mixing ratio suggests that adsorption occurred 
via a non-stoichiometric electrostatic binding process.44,45 The model assumes that for each 
value of 𝑋𝑋, the polymers are equally distributed among the particles in the dispersion.45 Below 
𝑋𝑋!, the iron oxide surfaces are saturated with polymers, the functional end-groups exceeding 
the number of binding sites. Above, the coverage is incomplete and the particles precipitate 
upon 𝑝𝑝𝑝𝑝 increase (as uncoated particles do). Here, we exploit this feature to derive the number 
of adsorbed chains per particle 𝑛𝑛!"#:
12 
𝑛𝑛!"! =
1
𝑋𝑋!
𝑀𝑀!
!"#$
𝑀𝑀!
!"#                                                                                                                                           (1)	  
where 𝑀𝑀!!"#$ and 𝑀𝑀!!"# are the particle and polymer molecular weights, respectively. For PEG2K 
on 6.8 nm and 13.2 nm particles, 𝑋𝑋! = 1.3 and 5, leading to a number of adsorbed polymers 
𝑛𝑛!"# = 97 and 207, respectively. For PEG5K, 𝑋𝑋! = 0.5 and 2, resulting in 𝑛𝑛!"# = 43 and 88 (Table 
S5). These 𝑛𝑛!"#-values correspond to a PEG density of 1 - 2 nm
-2. With zeta potentials of -6 
mV, electrokinetic measurements confirmed that the multi-phosphonic acid PEG coated 
particles were globally neutral (S4). Before use, the dispersions were finally dialyzed against 
deionized water using a 50 kD cut-off membrane to remove the excess polymer, and further 
concentrated by ultrafiltration. They were then autoclaved (Tuttnauer Steam Sterilizer 2340M) at 
120 °C and atmospheric pressure during 20 min to prevent bacterial contamination, and stored 
at 4 °C in a secure environment. 
Citric acid is a weak triacid of molecular weight 𝑀𝑀! = 192 Da, with acidity constants pKA1 = 3.1, 
pKA2 = 4.8 and pKA3 = 6.4. Surface charge complexation with citric acid was performed during 
the synthesis through simple mixing. At pH 8, citric acid molecules are ionized, and particles are 
coated with citrate ions. As ligands, citrates are characterized by adsorption isotherms and 
adsorbed species are in equilibrium with free citrates in the bulk. The free citrate concentration 
was kept at the value of 8 mM,39 both in DI-water and in culture medium. The hydrodynamic 
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citrate coated particle diameter was identical to that of bare particles, indicating a layer thickness 
under 1 nm.  
Poly(sodium acrylate), the salt form of poly(acrylic acid) with a weight-average molecular weight 
𝑀𝑀! = 2.1 kDa and a dispersity of 1.7 was purchased from Sigma Aldrich and used without 
purification. To adsorb polyelectrolytes on the particles, the precipitation-redispersion protocol 
was applied.41 The precipitation of the iron oxide dispersion by PAA2K was performed in acidic 
conditions (pH2). The precipitate was then separated by magnetic sedimentation and its pH was 
increased by ammonium hydroxide addition. The precipitate redispersed spontaneously at pH8. 
PAA2K coated γ-Fe2O3 hydrodynamic sizes were around 4 – 6 nm larger than the hydrodynamic 
diameter of the uncoated particles, indicating a corona thickness of 2 – 3 nm. Electrophoretic 
mobility and zeta-potential values are provided in the Supporting Information section (S4). As 
for the multi-phosphonic acid PEG coated particles, the dispersions were dialyzed and 
autoclaved to prevent bacterial contamination.  
 
 
2.2 - Methods 
2.2.1 - Dynamic light scattering (DLS) 
Light scattering experiments were performed on a NanoZS spectrometer (Malvern) at the 
wavelength of 633 nm and in backscattering configuration (scattering angle 173°). From the 
scattered intensity evolution, the second-order autocorrelation function of the light is calculated 
and analyzed using different procedures provided by the instrument software. These 
procedures are the cumulant method and the CONTIN algorithm. Both gave consistent values 
for the hydrodynamic diameter 𝐷𝐷!. As mentioned previously, the nanoparticle hydrodynamic 
diameters are found to be systematically larger than those obtained by other techniques, in 
particular by electron microscopy and magnetometry (Table I). The reason for this difference is 
related to the particle size distribution, along with the fact that light scattering is sensitive to the 
largest objects of the distribution. 
 
2.2.2 - Cell Culture 
Adherent cells from mouse hepatocyte cells BWTG3 were studied. Hepatocyte cells BWTG3 
were grown in T25-flasks as a monolayer in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
high glucose (4.5 g L-1) and stable glutamine (PAA Laboratories GmbH, Austria). The medium 
was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (PAA 
Laboratories GmbH, Austria). Exponentially growing cultures were maintained in a humidified 
atmosphere of 5% CO2 and 95% air at 37°C, and in these conditions the plating efficiency was 
70 – 90% and the cell duplication time was 12 – 14 h. Cell cultures were passaged twice weekly 
using trypsin–EDTA (PAA Laboratories GmbH, Austria) to detach the cells (6 millions in 
average for T25 flasks) from their culture flasks and wells. The cells were pelleted by 
centrifugation at 1200 rpm for 5 min. Supernatants were removed and cell pellets were re-
suspended in assay medium and counted using a Malassez counting chamber.  
 
2.2.3 - Toxicity assay 
The method measured the cellular mitochondrial activity. Subconfluent cell cultures (60% 
confluency at treatment time) on 96 well plates were treated with 100 µL/well of nanoparticles at 
different concentrations for 24 h, culture medium was removed, cells were rinsed with culture 
media without phenol red and incubated with 100 µL/well of 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulphophenyl)-2H-tetrazolium (WST-1, Roche Diagnostics), diluted 1/10 in culture 
medium without phenol red for 1 to 4 h. The assay is based upon the reduction of the 
tetrazolium salt WST-1 to formazan by cellular dehydrogenase. The generation of the dark 
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yellow colored formazan was measured at 450 nm in a multiwell-plate reader against a blank 
containing culture media and WST-1 and it was corrected from the absorbance at 630 nm. The 
supernatant optical density is directly correlated to cell number. 
 
2.2.4 – Relaxometry 
Images were acquired with a 7 Tesla spectrometer equipped with a 1H radiofrequency linear coil 
of inner diameter 40 mm (Bruker, Karlsruhe Germany). 𝑇𝑇! and 𝑇𝑇! relaxation times were 
measured on 200 µL solutions with increasing iron concentrations, [Fe] = 0.02, 0.05, 0.1, 0.2 
and 0.5 mM to determine the longitudinal and transverse relaxivities 𝑟𝑟! and  𝑟𝑟!. For 𝑇𝑇!-
measurement, a saturation sequence with 8 different repetition times from 60 ms to 15 s was 
used to evaluate the proton spin-lattice recovery. The field of view was of a 3×3×0.15 cm3 with 
a pixel resolution of 0.234×0.234×1.5 mm3 in all protocols. For 𝑇𝑇!-measurement, a sequence 
with 32 sequential echo times from 11 ms to 385 ms was applied to follow the decay of the 
proton spin-spin relaxation. The total scan time was 30 min. The relaxivities rates 𝑟𝑟!,! were 
obtained by adjusting the signal intensity of each agent at different concentrations using:46 
1 𝑇𝑇!,! = 𝑟𝑟!,![Fe]+ 1 𝑇𝑇!,!
! . These measurements were made in physiological saline solution and 
in DMEM with serum. 
 
2.2.5 - In vivo MRI (including data analysis) 
All animal work was performed in accordance with the institutional animal protocol guidelines in 
place at the University Paris-Descartes (Saisine CEEA34.JS.142.1) and approved by the 
Institute’s Animal Research Committee. Wild-type female 8 weeks BALB/c mice were 
anaesthetized by isoflurane inhalation (1.5% isoflurane in a 1:1 mixture of air and oxygen at the 
rate of 0.25 L min-1) and placed in a dedicated contention cradle in a 7 Tesla MR-scanner. 100 
µL of iron oxide nanoparticles in saline 0.9 wt. % with an optimized concentration of [Fe] = 5 mM 
were intravenously injected via the tail vein thanks to a catheter specifically elaborated for non-
magnetic use. The injected iron concentration was adjusted so that the hepatic uptake and 
clearance processes take a maximum of one week. For reproducibility studies, 2 to 4 mice were 
injected with the contrast agents tested. 13.2 nm citrate and PEG5K coated particles were 
injected on one mouse only. For imaging purposes, two types of time resolution were used 
sequentially: a high temporal resolution with low spatial resolution for the first 180 minutes, and 
a lower time resolution with high spatial resolution for time range between 20 min and 7 days. 
With this protocol, it was ensured that the early stage of the hepatic uptake could be evaluated 
accurately. The low spatial resolution scans were compared and normalized to the higher 
resolution images using a zero filling technique for signal optimization. All images were 
recorded with a field of view of 3×3 cm2, corresponding to an in-plane resolution of 125×125 
µm2 in both sequences. The scanning protocol was developed using Paravision 5.1 software. 
To minimize motion artifacts, two methods of respiratory synchronization were used. The high 
spatial, low temporal resolution sequence synchronized the acquisition with the mouse 
breathing cycles. The low spatial, high temporal resolution sequence used an internal navigator 
that detects the mouse respiratory and cardiac cycles and reconstructs the images in a post-
processing operation. This second method is independent of the breathing cycle changes. The 
time frame was set to one minute for the fast scans and three minutes for the slower scan. To 
recapitulate the chronological imaging experiments, images were recorded before injection and 
during the first 20 min at a rate of one image per minute, then at 30 min, 40 min, 1 h, 1h40, 
2h40, 4h, 7h20 and at 1, 2, 3, 4 5, and 7 days after injection. 3 mice per days were investigated 
with the addition of 3 to 9 mice in the follow-up process between one day and one week. To 
study the probe biodistribution, several organs including liver, spleen, kidney and arteries 
(Supporting Information S6) were monitored. Comparison with commercial Cliavist® was also 
performed. 
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3 - Results and Discussion 
3.1 - Iron oxide based contrast agents and coating 
Iron oxide nanoparticles of diameters 6.8 nm and 13.2 nm were synthesized by alkaline co-
precipitation of iron salts and subsequent oxidation into maghemite (γ-Fe2O3) and coated with 
different macromolecules.36,37 As coating agent, we used a statistical copolymer that combines 
multiple phosphonic acid groups and poly(ethylene glycol) chains on the same backbone. The 
full name of the polymer is poly(ethylene glycol methacrylate-co-dimethyl(methacryoyloxy) 
methyl phosphonic acid), abbreviated phosphonic acid PEG copolymer in the sequel of the 
paper. Synthesized by free radical polymerization (Specific Polymers®, France), the polymers 
were designed to strongly adsorb onto metal and metal oxide surfaces via the multiphosphonic 
acid groups.12 Copolymers with 2 kDa and 5 kDa PEG chains were synthesized and studied.  
The aforementioned PEGylated copolymers were compared to other coating types, including 
citric acid and poly(acrylic acid) polymer (PAA). Citric acid is a well-known and widely used 
coating for inorganic particles. In the molecular imaging context, citrate coated particles were 
tested in a clinical phase I trial to evaluate their pharmacokinetics and safety.47 Poly(acrylic 
acid) in contrast was less studied and to our knowledge the biodistribution of PAA coated 
contrast agents was not reported yet. In vitro, it was shown that PAA coat is biocompatible and 
non-toxic, and that the charged polymer layer brings significant protection against protein 
adsorption and particle agglomeration.9,48-50 A recent in vivo study has revealed however acute 
effects on cardiovascular function.49 The chemical formulae, charge and molecular weights of 
the coating agents probed are summarized in Fig. 1b. More details on the coating and 
characterization methods are given in the M&M section.  
 
Important parameters for the particles are the total hydrodynamic diameter 𝐷𝐷! and the coating 
thickness ℎ, which were determined by light scattering (Table III). The polymer layers were 
found to have the same thickness for the 6.8 and for the 13.2 nm particles, and to agree with 
the brush structure.51,52 In good solvent conditions, PEG2K is a chain of gyration radius 1.3 nm,53 
whereas its fully stretched length is about 10 nm. ℎ-values of 5 ± 1 nm (Table III) are 
intermediate and indicate that the chains at the surface are slightly stretched, typically by 40 – 
50 %. The PEG5K layer on the 6.8 nm iron oxide has a thickness of 16 ± 2 nm, which 
corresponds to a higher stretched configuration.52 PAA layers have a thickness of 2 – 3 nm, as 
mentioned in earlier work.9,40,44,50  
 
nanoparticles	   coating	   hydrodynamic	  
diameter	  	  	  𝐷𝐷!	  
nm	  
Layer	  thickness	  
ℎ	  
nm	  
γ-­‐Fe2O3	  
6.8	  nm	  
bare	   14	  ±	  1	   0	  
citrate	   15	  ±	  1	   0.5	  ±	  1	  
PAA2K	   18	  ±	  1	   2	  ±	  1	  
PEG2K	   22	  ±	  1	   4	  ±	  1	  
PEG5K	   46	  ±3	   16	  ±	  2	  
	   	   	   	  γ-­‐Fe2O3	  
13.2	  nm	  
bare	   27	  ±	  1	   0	  
citrate	   28	  ±	  1	   0.5	  ±	  1	  
PAA2K	   33	  ±	  1	   3	  ±	  1	  
PEG2K	   37	  ±	  2	   5	  ±	  1	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PEG5K	   44	  ±	  3	   8.5	  ±	  2	  
	   	   	   	  Cliavist©	  
4	  nm	  
carboxy	  
dextran	  
66	  ±	  4	   aggregates	  
	   	   	   	   
Table III: Characteristics of the iron oxide particles used in this work. 𝐷𝐷! denotes the particle 
hydrodynamic diameter and ℎ the coating thickness as determined from dynamic light scattering 
measurements. Data for Cliavist® are from ref.1 The error bars denote here the standard deviations. 
 
 
3.2 - Stability in physiological and culture media 
As for the evaluation of protein corona and particle agglomeration, the following protocol was 
applied.9,44 A few microliters of a concentrated dispersion are poured and homogenized rapidly 
in 1 mL of the solvent to be studied, and simultaneously the scattered intensity 𝐼𝐼! and diameter 
𝐷𝐷! are measured by light scattering. After mixing, the measurements are monitored over a 2-
hour period, and subsequent measurements are made after 24 hours and 1 week. 
Nanoparticles are considered to be stable if their hydrodynamic diameter 𝐷𝐷! in a given solvent 
remains constant as a function of the time and equal to its initial value (given in Table III). 
Solvents surveyed here are DI-water (pH 7.4), phosphate buffer saline (PBS) and cell culture 
medium (Dulbecco’s Modified Eagle’s Medium, DMEM) with or without calf bovine serum. 
Stability assays were performed on bare and coated iron oxide nanoparticles (Fig. 2). The 
commercial contrast agent Cliavist® was used as a benchmark. Bare particles with diameters 
6.8 nm and 13.2 nm are stable at pH 1.8 (the pH at which they are synthesized) and stabilized 
by surface charges. Under rapid dilution, the pH variation induces a modification of the 
electrostatic charges at their surfaces. At physiological pH, the dispersions are close to their 
isoelectric point54 (IP 6.7) and the particles are slightly positive. Bare particles hence aggregate 
due to van der Waals interactions. Citrate and carboxydextran (Cliavist®) coated particles are 
stable in PBS buffer. In culture media however, citrate coated particle precipitation occurs (Fig. 
2) and it is attributed to the displacement of the ligands from the surfaces, as they are 
preferentially complexed by Ca2+ and Mg2+ divalent counterions.9 For Cliavist®, the 
destabilization also takes place and come from the loosely tethered carboxydextran chains at 
the iron oxide surface. The particles coated with polymers, either poly(acrylic acid) or 
phosphonic acid PEG copolymers exhibit in contrast an outstanding stability over time. The 
dispersions are found to remain stable for months. For particles with polymer coats, protein 
corona was also not detected.12,55 The stability results obtained in DMEM after one week are 
summarized in Fig. 2.  
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Figure 2: a) Hydrodynamic diameter 𝐷𝐷! versus time for contrast agents after they have been diluted in 
Dulbecco’s Modified Eagle’s Medium (DMEM). For uncoated particles, and for particles coated with 
citrates, aggregation and precipitation occur rapidly, as indicated by the initial size increase. For cliavist®, 
the aggregation is slower, but is still visible on the time scale of a week. Particles coated with poly(acrylic 
acid) and phosphonic acid PEG copolymers were found to remain stable for months. b-e) Images of 
some selected iron oxide dispersions in DMEM after one week. Stability assays were performed at 
experiments at the weight concentration of 0.1 wt. %. 
 
3.3 - Relaxometry 
The longitudinal and transverse relaxivities 𝑟𝑟! and  𝑟𝑟! of the coated particles dispersed in DI-
water and in cell culture medium were measured using 𝑇𝑇!- and  𝑇𝑇!-weighted MR images on a 7.0 
T on a 300 MHz micro-imaging Bruker spectrometer. Dispersion weighted phantom images at 
molar concentration [Fe] = 0, 0.02, 0.05, 0.1, 0.2 and 0.5 mM were acquired, and their greyscale 
intensity was found to decrease with concentration, a result that is explained by the dipolar 
coupling between the magnetic moments and the water protons. In this range, the inverse of the 
relaxation times was found to vary linearly with [Fe], according to: 1 𝑇𝑇!,! = 𝑟𝑟!,![Fe]+ 1 𝑇𝑇!,!!  
where  𝑇𝑇!,!!  denotes the water longitudinal and transverse relaxation time.
46,56 Fig. 3a and 3b 
display the transverse relaxivity 𝑟𝑟! histograms for the two particle sizes and for the various 
coatings. Comparison with Cliavist® is also shown (Fig. 3c). The relaxivities 𝑟𝑟!,! and relaxivity 
ratios 𝑟𝑟! 𝑟𝑟! are listed in the Supporting Information Section (S7).  
Data in Fig. 3 show that the particle core size has a strong impact on the contrast, as 𝑟𝑟! passes 
from 62 mM-1 s-1 to 171 mM-1 s-1 for uncoated particles, and from 74 mM-1 s-1 to 226 mM-1 s-1 for 
the PEGylated ones. This increase is in agreement with that reported in Vuong et al. 42 who 
suggested that the iron based contrast agent transverse relaxivity grows quadratically with 
particle size. As for the coating, the data also show that the presence of a layer around particles 
leaves 𝑟𝑟! rather unchanged and increases 𝑟𝑟! by 20% in average. With respect to the solvent, 
the effect is the strongest with uncoated particles. From DI-water to cell culture medium, the 
transverse relaxivity of 6.8 nm γ-Fe2O3 is multiplied by a factor of 4 (from 62 mM-1 s-1 to 284 mM-
1 s-1), whereas it is increased by a factor of 1.5 for the 13.2 nm particles (from 171 to 272 mM-1 
s-1). This increase is consistent with particles being incorporated into large micron-sized 
aggregates, as shown in Fig. 2.42,57 In conclusion, we have found that for maghemite the coating 
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has a relatively weak impact on 𝑟𝑟! and 𝑟𝑟!. These findings are important for the later in vivo MR 
imaging results, as they suggest that the role of the coating can be determined independently of 
other parameters.  
 
 
Figure 3: Transverse relaxivity 𝑟𝑟! measured at 7 Teslas for 6.8 nm (a) and 13.2 nm (b) iron oxide 
nanoparticles dispersed in aqueous media. The data for Cliavist® (c) are shown for comparison. The 
error bars are defined as the standard deviations. 
 
 
3.4 - Biocompatibility and toxicity 
Murine hepatocyte cells BWTG3 viability was studied using the colorimetric assay WST-1. 
WST-1 was performed at iron dose levels between 10-3 mM to 10 mM, to cover a broad 
concentration range and specifically the concentration used in vivo ([Fe] = 0.5 mM in the blood 
pool). Fig. S8 a-f display the percentage of viable BWTG3 cells treated during 24 h with 
Cliavist® and with the 6.8 nm and 13.2 nm iron oxides. For the 11 particles studied, the viability 
exhibits a slight to moderate decrease around [Fe] = 0.5 - 5 mM, the effect being the strongest 
for bare and citrate coated particles. This latter result could be related to the particle 
agglomeration and sedimentation, which increase the amount of materials adsorbed at the 
plasma membrane.55 Observations of cells in situ using optical microscopy indicate that the 
cellular morphology was modified at high dose levels. Except for bare particles, the BWTG3 
hepatoma cells exhibit a viability above 50% for all coating. These findings corroborate results 
obtained with other cell lines, including NIH/3T3 mouse fibroblasts,50 2139 Human 
lymphoblasts9 and RAW264.7 macrophages.12 Viability experiments with the coating agents 
alone, including phosphonic acid PEG copolymers, citrate and PAA polymers, were also done 
and reveal no cytotocity at relevant concentrations.9,12,50  
 
3.5 - 𝑻𝑻𝟐𝟐-weighted MR Imaging of the liver: particle size and coating 
effects 
The uptake of intravenously injected contrast agents was monitored by measuring the signal 
enhancement on T2 weighted images of different organs. The iron oxide dispersion injected to 
the mouse was 100 µL and the iron concentration 5 mM (corresponding to 16.7 µmol kg-1 or 
0.93 mg kg-1). Previous reports have shown that iron oxide based contrast agents exhibit uptake 
times of the order of minutes and clearance times in the range of days.21-23,58-60 A logarithmic 
temporal scale was hence used for imaging the mouse organs at times ranging from one minute 
to one week. Fig. 4 compares MR scans obtained in the first three hours for Cliavist® (Fig. 4a to 
d) and for the 6.8 nm PEG2K particles (Fig. 4e to h). With the commercial agent, the mouse liver 
section exhibits a negative contrast enhancement shortly after injection (e.g. in Fig. 4b at 30 
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min). The darkening in the liver arises from the iron accumulation in the organ.1,21,22,58,60-63 Multi-
phosphonic acid PEG coated particles display a different behavior (Fig. 4e-g). For this sample 
the darkening is delayed by about 2 – 3 hours as compared to that of Cliavist®. During the 
period, the MR images show no contrast change of the liver and of other organs (spleen, 
kidneys), indicating a prolonged circulation in the bloodstream, as well as a delayed hepatic 
uptake (S6). At 3 hours post-injection (Fig. 4d and 4h), MR images exhibit a negative contrast 
enhancement as with cliavist®. A movie comparing the liver MRI intensity after injection of 
PAA2K and multi-phophonic acid PEG2K coated particles has been added as Supporting 
Information. 
 
 
Figure 4: Magnetic resonance imaging scans for wild-type female 8 weeks BALB/c mouse livers at 
different time points (30 min, 1 and 3 hours) after injection for Cliavist® (a to d) and for the 6.8 nm PEG2K 
coated particles (e to h). In the assays, 100 µL of a [Fe] = 5 mM dispersion were injected to the mouse. 
The corresponding dose is 16.7 µmoles, or equivalently 0.93 mg of iron per kilogram of mouse. A 
comparison of the two time sequences shows a delay in the negative contrast enhancement at about 3 
hours for the PEG particles, compared to that of the commercial contrast agent. 
 
 
To quantify the MR contrast, the liver mapping was performed by defining manually regions of 
interest (ROI), and by integrating the grey scale intensity as an 8-bit integer (between 0 and 
255). Spatially average intensities were obtained and normalized with respect to the pre-
injection level. With these conventions, the MRI signal intensity varies between 1 and 0, and the 
liver darkening is associated with a decrease as a function of the time (Fig. 5). The procedure 
was carried out at each time point for 8 particles: cliavist® (𝑛𝑛 = 3), 6.8 nm particles coated with 
PAA2K (𝑛𝑛 = 3), PEG2K (𝑛𝑛 = 4) and PEG5K (𝑛𝑛 = 2), and with 13.2 nm coated with citrate (𝑛𝑛 = 1), 
PAA2K (𝑛𝑛 = 2), PEG2K (𝑛𝑛 = 2) and PEG5K (𝑛𝑛 = 1). Here, 𝑛𝑛 designates the number of mice tested. 
Intravenous injection into the tail vein was performed as a single bolus in the conditions of Fig. 
4, i.e. 100 µL of dispersion at 5 mM. Fig. 5 illustrates the correspondence between the liver MR 
images and the greyscale intensity. In the pre-injection period, the intensity remains at the level 
of 1. The MR signal then decreases rapidly after injection and passes through a minimum.  
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Figure 5: a) to c) Magnetic resonance imaging scans of a wild-type female 8 week BALB/c mouse liver at 
different time points after injection for the 13.2 nm poly(acrylic acid) coated particles. The liver mapping 
(indicated as ROI in the images) was performed manually by defining regions of interest, and by 
integrating the greyscale intensity as an 8-bit integer. d) Illustration of the correspondence between the 
MR images and the greyscale intensity displayed in the left-hand side panel. In the pre-injection period, 
the intensity remains constant and then decreases rapidly after injection.  
 
 
In Fig. 6a and 6b, data for 6.8 nm and 13.2 nm particles coated with PAA2K and PEG2K are 
compared. For the poly(acrylic acid) coated nanoparticles, as well as for Cliavist®, the MRI 
signal intensity exhibits a broad minimum down to 0.35. For these samples, the minimum 
extends over a period of tens to hundreds of minutes. At longer timescale, typically from 1 to 7 
days after injection the MRI signal intensity increases again and reaches unity, indicating that 
the liver returns to its pre-injection level. This recovery is associated with the iron clearance out 
of the liver.21,58-60 On the opposite, PEGylated 6.8 nm and 13.2 nm particles exhibit prolonged 
circulations in the blood pool, the contrast enhancement appearing approximately after 2 – 3 
hours. Later, the MRI signal passes through a minimum as in the previous case, and recovers 
its pre-injection limit after a few days. Interestingly, the MRI level at the minimum (around 0.6) 
remains higher than for anionic particles, indicating a lower iron oxide concentration and a 
reduced uptake 
Concerning the polymer molecular weight, earlier studies have shown that the coating efficiency 
increases with the layer thickness.1-3,6,15,23,25,26 To test this assumption, the pharmacokinetics of 
identical core particles with 2 kDa and 5 kDa PEG coating was investigated. From light 
scattering experiments, the layer thickness associated to PEG2K and PEG5K polymers was 
estimated at 5 nm and 8 nm, respectively (Table III). Fig. 7a and 7b compare the MRI signal 
intensity for the two particles. For 6.8 nm particles, the hepatic uptake is progressive and slightly 
more rapid for PEG5K than for PEG2K. The difference may come from the hydrodynamic 
diameter that is about twice larger with the longer polymer, or from a lower PEG density (S5). 
For the 13.2 nm particles, the time dependent contrast enhancements remain similar in terms of 
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hyposignal kinetics and amplitude. Combined together, these results show that the optimum 
stealthiness in vivo is obtained for the 6.8 nm particles and a 2 kDa PEG coating.  
 
    
Figure 6: Time dependences of the MRI signal intensity for a) 6.8 nm and b) 13.2 nm PAA2K and PEG2K 
coated nanoparticles. Cliavist® is shown for comparison. In the in vivo experiments, the iron oxide 
dispersion injected to the mouse was 100 µL and the iron concentration 5 mM (corresponding to 16.7 
µmol kg-1 or 0.93 mg kg-1). With the conventions used, the darkening of the liver is associated to a 
decrease of the MRI signal as a function of the time. The error bars indicate the standard deviations. 
Figure 7: Time dependences of the MRI signal intensity for a) 6.8 nm and b) 13.2 nm nanoparticles 
coated with PEG2K and PEG5K. Cliavist® is shown for comparison. The experimental conditions are 
similar to those of Fig. 6. The error bars indicate the standard deviations. 
 
3.6 - Quantitative analysis of iron uptake and release by the liver  
To retrieve the contrast agent pharmacokinetics parameters, the MRI signal intensity was 
adjusted using an expression of the form:  
𝐹𝐹!"# 𝑡𝑡 = 𝛼𝛼 + 1 − 𝛼𝛼 𝑒𝑒𝑒𝑒𝑒𝑒 −
!
!!"
!
+ 1 − 𝛼𝛼 1 − 𝑒𝑒𝑒𝑒𝑒𝑒 −
!
!!"#$%
!
  (2) 
where 𝛼𝛼 is the intensity minimum, 𝜏𝜏!" and 𝜏𝜏!"#$% the characteristic times for uptake and 
clearance. In the above model, it is assumed that the two mechanisms are occurring one after 
the other. In a first attempt to adjust the MRI intensities, single exponentials were used but were 
found to be inappropriate. The single exponentials were replaced by stretched exponentials 
characterized by exponents 𝛽𝛽 for the uptake and 𝛾𝛾 for the clearance. Stretched exponential 
functions have been found to describe many phenomena in Nature, in particular in complex 
systems with broad relaxation time distribution.64,65 In Eq. 2, 𝜏𝜏!" and 𝜏𝜏!"#$% are related 
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respectively to the half-life times 𝑡𝑡!/!
!"  and 𝑡𝑡!/!
!"#$% that characterize the initial and terminal 
processes, via the expressions 𝑡𝑡!/!
!" = 𝜏𝜏!"(𝑙𝑙𝑙𝑙2)
!/! and 𝑡𝑡!/!
!"#$% = 𝜏𝜏!"#$%(𝑙𝑙𝑙𝑙2)
!/!. In the following, 
the data will be discussed in terms of the half-life times to ease comparison with earlier 
work.23,58 Fig. 8a–h show the MRI signal intensities obtained for the different systems and the 
least-square calculations results using Eq. 2 (continuous lines). For the eight samples 
considered, Eq. 2 provides a satisfactory outcome over the entire time range. The adjustable 
parameters 𝛼𝛼, the half-life times 𝑡𝑡!/!
!"  and 𝑡𝑡!/!
!"#$%, and the stretched exponents 𝛽𝛽 and 𝛾𝛾 are listed 
in Table IV.  
 
Figure 8: MRI signal intensity for the iron based contrast agents studied in this work, together with least-
square calculations using Eq. 2 (continuous lines). The fitting of the uptake and clearance kinetics allows 
to determine the following parameters: the intensity minimum 𝛼𝛼, the half-life times 𝑡𝑡!/!
!"  and 𝑡𝑡!/!!"#$% and the 
stretched exponents 𝛽𝛽 and 𝛾𝛾 (Table IV).  
 
 
As anticipated, the half-life time 𝑡𝑡!/!
!"  for the uptake mechanism depends strongly on the coating. 
For PAA2K 6.8 nm particles, the uptake time is estimated at 4.5 ± 0.3 min, whereas it is 55 times 
longer for PEG2K particles, at 249 ± 18 min. The stretch exponent for this mechanism varies 
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from 𝛽𝛽 = 0.4 − 0.6 for the agents that are rapidly uptaken, to 𝛽𝛽 = 3 for the stealthiest ones. In 
Table IV, the size effect can be clearly seen as 6.8 nm particles have systematically prolonged 
circulation times as compared to the 13.2 nm particles.1 The results suggest that the uptake 
mechanism depends primarily on two parameters, the probe size and the coating type. In the 
present study, the effects of each of these parameters are separately identified.  
 
The clearance phenomenon is associated with the particle degradation and with the iron 
incorporation into the main intracellular iron storage proteins (ferritin, hemosiderin).58,59 The MRI 
signal intensity returns to its pre-injection level as iron oxide particles are metabolized and their 
degradation products cleared (Fig. 8). As can be seen from Table IV, a rather uniform kinetics is 
observed for the clearance, with half-life times between 2 to 4 days. Indeed, 𝑡𝑡!/!
!"#$% does not 
depend on the magnetic core sizes, nor on the coating. The benchmark agent Cliavist® exhibits 
also a comparable clearance time (𝑡𝑡!/!
!"#$% = 2.6 ± 0.1 day).  
 
γ-­‐Fe2O3	   coating	   𝛼𝛼	   𝑡𝑡!/!
!" 	  
(min)	  
𝛽𝛽	   𝑡𝑡!/!
!"#$% 	  
(day)	  
𝛾𝛾	  
6.8	  nm	   PAA2K	   0.45	   4.5	  ±	  1.3	   0.46	   2.8	  ±	  0.2	   1.6	  
PEG2K	   0.62	   249	  ±	  18	   3.0	   4.0	  ±	  0.3	   1.4	  
PEG5K	   0.65	   103	  ±	  15	   1.2	   1.5	  ±	  0.3	   1.6	  
	   	   	   	   	   	   	  13.2	  nm	   citrate	   0.40	   2.5	  ±	  0.2	   0.42	   3.9	  ±	  0.2	   1.0	  
PAA2K	   0.30	   1.4	  ±	  0.3	   0.60	   2.8	  ±	  0.3	   0.4	  
PEG2K	   0.50	   82	  ±	  13	   0.80	   2.8	  ±	  0.6	   1.8	  
PEG5K	   0.54	   59	  ±	  15	   1.2	   n.d.	   n.d.	  
	   	   	   	   	   	   	  Cliavist®	   Carboxy	  
dextran	  
0.42	   6.0	  ±	  1.2	   0.40	   2.6	  ±	  0.1	   1.3	  
	   	   	   	   	   	   	   
Table IV: Parameters obtained from the adjustment of the MRI signal intensity with Eq. 2. 𝛼𝛼 denotes the 
intensity minimum, 𝑡𝑡!/!
!"  and 𝑡𝑡!/!!"#$% the half-life times associated to the uptake and clearance mechanisms 
and 𝛽𝛽 and 𝛾𝛾 the stretched exponential exponents. The error bars are defined as the standard deviations 
(SD). 
 
 
4 - Conclusion 
In this work, novel iron oxide based contrast agents dedicated to in vivo magnetic resonance 
imaging were synthesized, with the aim of understanding the relationship between the particle 
coating properties and their pharmacokinetics. Maghemite (γ-Fe2O3) particles with diameters 6.8 
nm and 13.2 nm were prepared and coated following bottom-up assembly processes. Different 
organic macromolecules were considered and a total of 10 different probes were evaluated both 
in vitro and in vivo. Statistical copolymers (Specific Polymers®, France) combining multiple 
phosphonic acid groups and PEG chains on the same backbone were synthesized and used as 
coats for iron oxide particles. These polymers were characterized by 2 kDa and 5 kDa 
PEGylated side-chains.  
The particles were first evaluated regarding their physico-chemical properties and characterized 
in terms of size, charge and coating thickness. The colloidal stability, protein adsorption in 
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culture media, contrast agent relaxometry and probe toxicity were investigated. The first result 
that emerges from the in vitro assay is that polymers, either poly(acrylic acid) or poly(ethylene 
glycol) are efficient coatings, as they prevent particles to agglomerate in culture media or to be 
covered by plasma proteins. The particles and the PEG based polymers were found to be non-
toxic and biocompatible at the in vivo dose level. 
The dispersions were injected intravenously into the mouse tail vein at a relatively low dose 
(16.7 µmol of iron per kilogram of mouse) compared to earlier reports. Liver, spleen and kidneys 
𝑇𝑇!-MR images were acquired prior and after injection, at time points between one minute and 
seven days. As nanoparticles are eliminated by the reticulo-endothelial system and filtered by 
the liver, the change in the liver MRI contrast was investigated and provided a direct indication 
of the nanoparticle pharmacokinetics. With this protocol, the particle uptake and clearance time 
evolution in and out of the liver could be retrieved. The main outcome from the in vivo MRI 
mouse assays is that coating appears as the primary parameter that affects the liver uptake 
kinetics and elimination from the blood pool. Phosphonic acid PEG2K-copolymers provides the 
most efficient contrast agent in terms of stealthiness, as they are able to prolong the blood 
particle lifetime up to 250 minutes. In similar conditions, the life times for citrate and PAA2K 
coated particles are typically 50 times shorter. Although poly(acrylic acid) is a robust coating 
ensuring colloidal stability in vitro, its in vivo performance is comparable to that of citrate or 
dextran. The time at which the MRI signal intensity returns to its pre-injection level was found to 
follow a more universal behavior. The clearance time was comprised between 2 to 4 days for all 
samples studied, including the commercial benchmark Cliavist®. In conclusion, we have shown 
that a 5 nm layer made of multi-phosphonic acid poly(ethylene glycol) at the iron oxide surface 
significantly improve the colloidal stability, protein adsorption properties and stealthiness in vivo 
of MRI probes. Our work also demonstrates that the phosphonic acid coupled to innovative 
polymer synthesis may open up new horizons regarding the surface functionalization. 
 
Supporting Information 
The Supporting Information includes sections on the iron oxide nanoparticle characterization in 
S1 (transmission electron microscopy), S2 (electron beam microdiffraction), S3 (vibrating 
sample magnetometry) and S4 (zeta potential). The PEG density determination at the particle 
surface is described in S5, the nanoparticle distribution kinetics in abdominal aorta in S6, the 
longitudinal and transverse relaxivity measurements in S7 and the cytotoxicity studies using 
murine hepatocytes in S8. 
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